Dr Melvyn Damast, MD in Exeter, NH - Ophthalmology

Dr Melvyn Damast, MD is a Ophthalmology physician based in Exeter, New Hampshire. Dr Melvyn Damast is licensed to practice in New Hampshire (license number NH7538) and his current practice location is 19 Hampton Rd, Exeter, New Hampshire. He can be reached at his office (for appointments etc.) via phone at (603) 772-3456.

NPI number for Dr Melvyn Damast is 1174634711 and his current mailing address is 19 Hampton Rd, Exeter, New Hampshire. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1174634711.

Contact Information

	Dr Melvyn Damast, MD
	19 Hampton Rd, Exeter, NH 03833-4816
	(603) 772-3456
	(603) 772-4912

Physician's Profile

Full Name	Dr Melvyn Damast
Gender	Male
Speciality	Ophthalmology
Location	19 Hampton Rd, Exeter, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1174634711
Provider Enumeration Date: 08/31/2006
Last Update Date: 10/22/2008

Medical Identifiers

Medical identifiers for Dr Melvyn Damast such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1174634711	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	NH7538 (New Hampshire)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Melvyn Damast is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Melvyn Damast, MD 19 Hampton Rd, Exeter, NH 03833-4816 Ph: (603) 772-3456	Dr Melvyn Damast, MD 19 Hampton Rd, Exeter, NH 03833-4816 Ph: (603) 772-3456

News Archive

Essen Instruments, Origene Technologies partner to co-develop ion channel cell lines

Essen Instruments Inc. and OriGene Technologies, Inc. today announced a strategic alliance to co-develop ion channel cell lines. Essen, based in Ann Arbor Michigan, is a leading provider of life science products and services, including ion channel discovery and safety assays. OriGene, headquartered in Rockville, Maryland, specializes in the creation and supply of gene-centric products, and has a collection of over 30,000 human full length cDNA clones.

Experts in camouflage breaking can accurately detect target in less than a second,

After looking for just one-twentieth of a second, experts in camouflage breaking can accurately detect not only that something is hidden in a scene, but precisely identify the camouflaged target, a skill set that can mean the difference between life and death in warfare and the wild, investigators report.

Women's HIV/AIDS conference delegates develop action plan to foster women's, girls' leadership in fight against disease

Delegates on Saturday at the close of the first International Women's Summit on Women's Leadership and HIV and AIDS in Nairobi, Kenya, released a 10-point action plan that aims to foster leadership roles of women and girls in the fight against HIV/AIDS, the Nation/AllAfrica.com reports.

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

Dr Melvyn Damast, MD - Ophthalmology in Exeter, NH